Search

Search Constraints

You searched for: Author/Creator Wilson, Rosamund

Search Results

1. 345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis. (25th January 2023)

2. OX40L Inhibition Suppresses KLH‐driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof‐of‐Pharmacology for KY1005. Issue 5 (1st March 2022)

3. Placebo‐controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy. Issue 8 (11th July 2018)